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and 6.8% of patients, respectively) incurred MS-speciﬁc costs
of $12,830, $14,348, and $17,028/employee, respectively.
Finally, employees in Quintile 5 (highest cost, 4.4%, n = 34)
incurred MS-speciﬁc costs of $26,048/employee. Only 18% of
Quintile 1 had DMT, all subjects in Quintiles 2–4 used DMTs,
and 8.8% of Quintile 5 used no DMTs. Although not used for
quintile assignments, “other conditions” costs/employee were
higher in higher cost quintiles, and Quintile 5 non-MS drug
costs/employee were 6.1–8.6 times higher than Quintiles 1–4.
Similarly, indirect costs were generally higher in the more
expensive quintiles. Average ages were similar between quin-
tiles. Quintile 5 was only 47.1% female, while other quintiles
were >60% female. Wide variation in MS-speciﬁc and non-
speciﬁc costs exists among employees with MS. However,
patients in the highest cost quintile may have the most severe
disease, suffer from multiple conditions and receive other drug
treatments. Further investigation is needed to understand the
impact of comorbid conditions on severity.
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OBJECTIVE: Vasospasm is a common complication of aneurys-
mal subarachnoid hemorrhage (SAH), but its economic impact
has not been studied. In this study, we estimated the incremental
impact of angiographic and clinical vasospasm on inpatient costs
and length of stay (LOS) in a cohort of patients hospitalized for
SAH. METHODS: The study cohort consisted of 198 consecu-
tive patients who underwent either endovascular or surgical
treatment for SAH at Duke University Medical Center (DUMC)
from February 1999 to October 2004. Patients were divided into
three subgroups: clinical (+angiographic) vasospasm (n = 64),
angiographic vasospasm only (n = 51), and patients without
vasospasm (n = 83). Direct and overhead inpatient costs were
obtained from the DUMC cost accounting system. Costs for
physician services were assigned using 2006 Medicare reimburse-
ment rates for North Carolina based on CPT codes billed for
physician services provided to patients in the study cohort. Gen-
eralized linear regression models were applied to assess the incre-
mental impact of vasospasm on inpatient costs and LOS while
adjusting for potentially confounding variables. A counterfactual
approach was applied to estimate the adjusted mean cost differ-
ence between subgroups deﬁned by the presence or absence of
vasospasm. RESULTS: The adjusted incremental cost attribut-
able to clinical vasospasm was $41,877, a 41% increase relative
to no vasospasm (95% CI: 23–62%, p < 0.0001). Angiographic
vasospasm was associated with a $24,528 incremental cost, a
24% increase (95% CI: 7–44%, p = 0.0043). LOS was estimated
to be 6.3 days or 39% longer with clinical vasospasm (95% CI:
21–61%, p < 0.0001), and 4.5 days or 28% longer with angio-
graphic vasospasm (95% CI: 9–50%, p = 0.0026) relative to no
vasospasm. Higher costs related to vasospasm remained signiﬁ-
cant after adjusting for differences in LOS. CONCLUSION:
Patients with clinical and/or angiographic vasospasm incur
higher inpatient costs than those without due to longer hospital
stays and receipt of higher intensity care.
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OBJECTIVE: To determine the economic impact of acute medi-
cation overuse among members with migraine or headache
enrolled in a large, national managed care organization (MCO).
METHODS: Commercial MCO members with a diagnosis of
migraine or headache and acute medication prescriptions from
2002–2006 comprised the study population. A novel claims-
based algorithm based on literature review and clinical expert
input was created to establish thresholds of potential overuse.
Two cohorts were identiﬁed: members with evidence of acute
medication overuse (MO) and members without evidence of
medication overuse (non-MO). Cohorts were followed over vari-
able time periods and compared on demographics, comorbidi-
ties, health care resource utilization and costs. RESULTS: A total
of 17,202 individuals met the criteria for medication overuse,
45,659 comprised the non-MO cohort. Most MO patients met
the criteria for medication overuse by exceeding the threshold for
opiates (62%) or triptans (38%). The MO cohort had signiﬁ-
cantly greater migraine/headache-related and all-cause resource
utilization compared with the non-MO cohort. On a per subject
per month basis, all-cause medical costs for the MO cohort were
$1236 compared with $185 for the non-MO cohort (<0.0001);
all-cause pharmacy costs were $483 for the MO cohort and $105
for the non-MO cohort (<0.0001). For migraine/headache-
related medical and pharmacy costs, total medical costs per
subject per month were $209 for the MO cohort and $33
(<0.0001) for the non-MO cohort, while pharmacy costs were
$286 for the MO cohort and $46 (<0.0001) for the non-MO
cohort. CONCLUSION: Members of this MCO with migraine
or headache who overused acute medications utilized more
health care resources and incurred greater costs compared with
members without acute medication overuse. These results
suggest the possibility that alternate treatment strategies that
decrease medication overuse may result in less health care
resource utilization and lower costs.
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OBJECTIVE: Little is known about medical expenditures in the
multiple sclerosis population after the introduction of expensive
disease modifying agents in the 1990s. This study examines new
data from 2000–2005 population-based survey of MS to provide
estimates of health services utilization by disease severity and
controlling for other risk factors. METHODS: We used a sub-
sample (n = 919) of patients with relapsing remitting and second-
ary progressive MS from the Sonya Slifka Longitudinal Multiple
Sclerosis Study that follows a nationally representative cohort of
MS patients. We examined utilization of hospital and outpatient
care, emergency room (ER), therapy, mental health services,
alternative medicine, home health and personal care. For most
utilization categories, we used log-linear negative binomial
regression models to estimate mean utilization, accounted for
possible correlation of observations for the same person by using
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